surpass 2 tirzepatide Read now: The SURPASS-EARLY trial found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Overview of the SURPASS clinical

You see in Canada tirzepatide is formally approved for use in type 2 diabetes, however physicians regularly prescribe it off label (meaning for a condition it is not yet formally indicated by regulators) for use with obesity while we wait for Health Canada approval (the FDA approved it for obesity on November 8th, 2023, while the EUs European Commission approved it for obesity on April 24th, 2024)

Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype

A well-balanced diet is the best way to support healthy aging

Get medical help right away if you have: A rash over your whole body Shortness of breath Swelling of your face, tongue, or throat Extreme drowsiness, dizziness, or confusion Trouble breathing Fast heartbeat Sweating Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching

Most patients report noticeable appetite reduction within 12 to 48 hours of their injection, even before weight changes appear on the scale

Redox Biol 37:101715 Zhang J, Wang H, Yan X, Zhang L (2005) Comparison of short-term toxicity between Nano-Se and selenite in mice